Chou Jen-Wei, Cheng Ken-Sheng, Huang Chih-Wen
School of Medicine, China Medical University, Taiwan.
Intern Med. 2016;55(6):623-7. doi: 10.2169/internalmedicine.55.5712. Epub 2016 Mar 15.
Sorafenib has been approved to increase the survival in patients with advanced hepatocellular carcinoma. Acute pancreatitis is an uncommon complication of sorafenib treatment. Only a few cases of sorafenib-induced acute pancreatitis have been reported in the English literature. We herein present the case of a 56-year-old man with hepatocellular carcinoma treated with sorafenib at 200 mg once daily. After six days of treatment, he suffered epigastric pain. Laboratory tests showed markedly elevated serum amylase and lipase levels. Imaging studies demonstrated negative findings. Sorafenib-induced acute pancreatitis was diagnosed after reviewing his history. The sorafenib treatment was discontinued, and his symptoms were resolved seven days later. To date, this case had the shortest duration and the lowest dosage of sorafenib to have induced acute pancreatitis.
索拉非尼已被批准用于提高晚期肝细胞癌患者的生存率。急性胰腺炎是索拉非尼治疗罕见的并发症。英文文献中仅报道过少数几例索拉非尼诱发的急性胰腺炎病例。我们在此报告一例56岁男性肝细胞癌患者，接受索拉非尼治疗，每日一次，每次200毫克。治疗六天后，他出现上腹部疼痛。实验室检查显示血清淀粉酶和脂肪酶水平显著升高。影像学检查结果为阴性。回顾其病史后诊断为索拉非尼诱发的急性胰腺炎。索拉非尼治疗停药，七天后他的症状得到缓解。迄今为止，该病例是索拉非尼诱发急性胰腺炎中持续时间最短、剂量最低的。
